I am an assistant professor of biological chemistry and molecular pharmacology at the Dana-Farber Cancer Institute and Harvard Medical School and my lab is a chemical biology lab that focuses on the development of new chemical technologies for the study and treatment of cancer. Currently, our primary biological interest is in tumor hypoxia and we are actively engaged in the design and synthesis of new therapeutic and imaging agents targeting this unique chemical microenvironment. Hypoxia, which is characterized by regions of low oxygen content resulting from inadequate and disorganized vasculature in tumors, results in the reprogramming of cancer cells to enhance their invasiveness and progression toward metastasis. Onset of hypoxia is often associated with highly negative prognoses for patients for whom there are very few treatment options; radiotherapy as well as most chemotherapies are ineffective in these tumor microenvironments. I am honored to have been awarded the Karin Grunebaum Faculty Research Fellowship and excited for the research that it will enable in my lab moving forward.